gdc
FDA Approvals, News & UpdatesMultiple Myeloma

Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma

In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
October 2020 Vol 6 No 5

In August 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a BCMA-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received 4 or more previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. Blenrep is the first BCMA antibody, representing a new approach to the treatment of multiple myeloma.

The FDA approved Blenrep based on an open-label, multicenter clinical trial in which patients received Blenrep therapy by intravenous infusion once every 3 weeks, until their disease progressed or if they had unacceptable side effects.

The efficacy of Blenrep was established based on the overall response rate to treatment and the duration of the response. The overall response rate was 31%, and 73% of those who had a response to therapy with Blenrep had a response lasting 6 months or longer.

The most common side effects associated with Blenrep therapy included keratopathy, decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.

Blenrep is associated with a risk for serious vision-related side effects.

Share this:

Recommended For You
Breast CancerFDA Approvals, News & Updates
FDA Approved Margenza for Patients with Metastatic HER2-Positive Breast Cancer
In December 2020, the FDA approved Margenza (margetuximab-cmkb), a new targeted therapy, for the treatment of patients with metastatic HER2-positive breast cancer, representing an important new option for patients with this type of breast cancer that continues to progress despite different treatments.
FDA Approvals, News & UpdatesLung Cancer
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the first MET inhibitor that has been approved by the FDA.
FDA Approvals, News & UpdatesLung Cancer
Tagrisso Approved as Adjuvant Therapy for Patients with Lung Cancer and EGFR Mutations
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer.
FDA Approvals, News & UpdatesProstate Cancer
Orgovyx First FDA-Approved Oral Hormone Therapy for Patients with Advanced Prostate Cancer
In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.
Last modified: November 10, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country